PF-07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID-19 patients.

ABSTRACT: The ongoing pandemic of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) and subsequently, coronavirus disease 2019 (COVID-19), has led to the deaths of over 6.1 million people and sparked a greater interest in virology to expedite the development process for antivirals. The US Food and Drug Administration (FDA) granted emergency use authorization for three antivirals: remdesivir, molnupiravir, and nirmatrelvir. Remdesivir and molnupiravir are nucleoside analogs that undergo biotransformation to form active metabolites that incorporate into new viral RNA to stall replication. Unlike remdesivir or molnupiravir, nirmatrelvir is a protease inhibitor that covalently binds to the SARS-CoV-2 3C-like protease to interrupt the viral replication cycle. A recent study identified that rem

SUBMITTER: Hau RK 

PROVIDER: S-EPMC9283746 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature